

September 6, 2024

General Announcement:

Senju Pharmaceutical Co., Ltd.

Launch of Distribution of Software for Dry-eye Analysis

Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of software for dry-eye analysis in Japan as an option of RET-700, effective immediately, where the marketing authorization holder is Rexam Co., Ltd. (hereinafter “Rexam”).

The software can categorize three types of dry eye (aqueous deficient dry eye, decreased wettability dry eye, increased evaporation dry eye) with AI in non-invasive way. This will be assistance in dry-eye diagnosis.

This distribution will be implemented by way of a partnership between Senju and Rexam. Through this alliance, Senju and Rexam will further contribute to people’s ‘health and prosperity by the realization and synergy of Senju’s mission of the “Pursuit of happiness for all people”, and Rexam’s` policy the “Take boldly on any challenge, while putting ourselves in customer’s shoes”.

[Contact details for inquiries]

Medical Device Department, Senju Pharmaceutical Co., Ltd.

3-1-9, Kawara-machi, Chuo-ku, Osaka 541-0048, Japan

Mail: medical-device@senju.co.jp

URL: <https://www.senju.co.jp>